


Neal Gutterson  
Paul Oeller  
Application No.: 09/924,197  
Page 3

PATENT

If the Examiner believes a telephone conference would expedite prosecution of this application, please telephone the undersigned at 415-576-0200.

Respectfully submitted,



Annette S. Parent  
Reg. No. 42,058

TOWNSEND and TOWNSEND and CREW LLP  
Two Embarcadero Center, 8<sup>th</sup> Floor  
San Francisco, California 94111-3834  
Tel: (415) 576-0200  
Fax: (415) 576-0300  
PIT  
SF 1290918 v1

**VERSION WITH MARKINGS TO SHOW CHANGES MADE**

Please replace the paragraph beginning on page 20, line 4, with the following rewritten paragraph:

Oligonucleotides were used to amplify a fragment which is deleted at the 5' end of the PG ORF (deletes 111 amino acids at the amino terminus of PG) and contains convenient restriction sites for cloning into pKL3063 and performing subsequent cloning steps.

PG-5' (19-mer sense primer):

5'-CTGTTCAATCCATGGTTCC-3' (SEQ ID NO:2; note: the underlined bases differ from the native PG sequence and provide a NcoI site at the engineered ATG initiation codon).

PG-3' (31-mer antisense primer):

5'-GA[AGATCT]ATACTGCAGATTAATAATTATAC-3' (SEQ ID NO:3; note: the underlined bases differ from native PG sequence and provide a PstI site downstream of the TAA stop codon, a BglII site proximal to the engineered PstI site is indicated by brackets, and the stop codon is highlighted in bold letters)